Evaluation of the effects of endometrial scratching on angiogenic and anti-angiogenic growth factors

Phase 2

Conditions: nexplained repeated implantation failure (uRIF).
Female infertility, unspecified
N97.9

Registration Number: IRCT20210316050723N1

Lead Sponsor: Iran University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: Female

Target Recruitment: 20

Inclusion Criteria

Infertile women with unexplained repeated implantation failure (unknown definite causes of RIF) failed to conceive after three or more embryo transfer cycles using high-quality transferred embryos (at least one blastocyst ET cycle)
Age of 20 to 40 years
Body mass index (BMI) less than 25 kg/m2
Good response to stimulation of previous ovulation
Having at least two embryos with good grade
normal uterus results of hysterosalpingography (HSG) or hysteroscopy
Participant consent was required to join in the study and to complete the consent form

Exclusion Criteria

The thickness of the endometrium on the day of Human chorionic gonadotropin hormone injection is less than 7 mm
Women with congenital anomalies, intramural and subserosal myomas( larger than 5 cm)
Submucosal myoma
Women with endometrioma larger than or equal to 3 cm
With adhesions
With hydrosalpinx
Have previous uterine or ovarian surgery
Severe male factor infertility (sperm extraction from the testis, sperm freezing, sperm DNA fragmentation index equal to or above 16%) Patients with any specific medication
If the number of available embryos is less than 2 in the current cycle
Women with endometrial tuberculosis and those undergoing tuberculosis treatment
Have a history of diabetes, thyroid disease, any endocrine, genetic, infection or autoimmune disorder
Abnormal Pre-implantation Genetic Test (PGT) Results
Any specific medication
Failure to return the patient to prepare an endometrial sample
Women with severe pain during obtaining of tissue samples or the possibility of infection

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluation of gene expression. Timepoint: In the endometrial sample obtained in the luteal phase during days 19-23. Method of measurement: Using PCR Array method and based on the copy number.

Secondary Outcome Measures